Skip to main content
Premium Trial:

Request an Annual Quote

Tecan Places Hyb System, High-Resolution Scanners in ASU Personal Dx Center


Austrian tools vendor Tecan announced this week that Arizona State University researchers have acquired one of its hybridization systems and two of its scanners for the purpose of processing protein microarrays.

The HS 4800 Pro automated hyb station and two of Tecan's PowerScanner units were placed in the Virginia G. Piper Center for Personalized Diagnostics at ASU's Biodesign Institute. Joshua LaBaer, director of the center, said in a statement that the instruments will be used to synthesize proteins for analysis.

According to LaBaer, the center's approach involves printing the genes for the desired proteins on slides and then adding a cell-free extract that synthesizes the proteins in situ. "The proteins are made literally an hour before we test them," LaBaer said.

He described the Tecan additions as "real workhorses," as the HS 4800 Pro allows the center's researchers to "produce proteins in situ on the glass, wash them off, and even incubate them with samples, all in a single run, without any manual intervention at all." He added that ASU selected the PowerScanners because of their "combination of good autoloading features, images and software."

Tecan has been active in the proteomics arena in recent years. Last October, the company inked a co-marketing agreement with Berlin-based JPT Peptide Technologies. Under that agreement, Tecan and JPT will market JPT's PepStar catalog peptide arrays and services alongside Tecan's HS 4800 Pro and HS 400 Pro automated array hybridization stations (BAN 10/2/2012).

And in June 2011, Tecan announced that it had developed a sample preparation system in collaboration with the Translational Genomics Research Institute and the Biodesign Institute at ASU for proteomic biomarker discovery and validation.

Company representatives have told BioArray News in the past that protein array users represent its largest customer segment (BAN 6/1/2010).

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.